Filtered By:
Specialty: Endocrinology
Condition: Heart Failure
Education: Study

This page shows you your search results in order of date.

Order by Relevance | Date

Total 271 results found since Jan 2013.

Do SGLT2 inhibitors and GLP-1 receptor agonists modulate differently the risk of stroke ? Discordance between randomised controlled trials and observational studies
Diabetes Metab. 2023 Sep 5:101474. doi: 10.1016/j.diabet.2023.101474. Online ahead of print.ABSTRACTStroke represents a major burden in patients with type 2 diabetes, yet this cerebrovascular complication has been less carefully investigated than the risk of cardiovascular mortality, heart failure and renal disease. Some data suggested that glucagon peptide-1 receptor agonists (GLP-1RAs) exert a better protection against stroke than sodium-glucose cotransporter 2 inhibitors (SGLT2is). However, this conclusion was derived from indirect comparisons in absence of any head-to-head randomised controlled trial (RCT). The present...
Source: Diabetes and Metabolism - September 7, 2023 Category: Endocrinology Authors: Andr é J Scheen Source Type: research

Glycated hemoglobin variability and the risk of cardiovascular events in patients with prediabetes and type  2 diabetes mellitus: A post‐hoc analysis of a prospective and multicenter study
ConclusionHigh HbA1c variability in the highest quartile showed a statistically significant association with multiple adverse cardiovascular events in an Asian population. Minimizing HbA1c fluctuation during long-term follow up should be another important objective for type  2 diabetes patients.
Source: Journal of Diabetes Investigation - August 24, 2023 Category: Endocrinology Authors: Worapaka Manosroi, Mattabhorn Phimphilai, Nipawan Waisayanand, Supawan Buranapin, Chaicharn Deerochanawong, Siriluck Gunaparn, Arintaya Phrommintikul, Wanwarang Wongcharoen, for the CORE ‐Thailand investigators Tags: Original Article Source Type: research

An elevated likelihood of stroke, ischemic heart disease, or heart failure in individuals with gout: a longitudinal follow-up study utilizing the National Health Information database in Korea
ConclusionThe present findings suggest that individuals with gout in the Korean population, particularly those aged ≥ 60 years, were more likely to have stroke, ischemic heart disease, or heart failure.
Source: Frontiers in Endocrinology - August 23, 2023 Category: Endocrinology Source Type: research

Higher Risk of Incident Hyperthyroidism in Patients With Atrial Fibrillation
CONCLUSIONS: Our results provide insight into clinical risk factors for the development of hyperthyroidism in AF patients, as identified by the novel SAD HEC2 score. AF appears to be a common precursor of hyperthyroidism.PMID:37565329 | DOI:10.1210/clinem/dgad448
Source: The Journal of Clinical Endocrinology and Metabolism - August 11, 2023 Category: Endocrinology Authors: Pang-Shuo Huang Jen-Fang Cheng Jien-Jiun Chen Yi-Chih Wang Juey-Jen Hwang Cho-Kai Wu Chia-Ti Tsai Source Type: research

Role of GLP-1 receptor agonist in diabetic cardio-renal disorder: Recent updates of clinical and pre-clinical evidence
Curr Diabetes Rev. 2023 Aug 9. doi: 10.2174/1573399820666230809152148. Online ahead of print.ABSTRACTCardiovascular complications and renal disease is the growing cause of mortality in patients with diabetes. The subversive complications of diabetes such as hyperglycemia, hyperlipidemia and insulin resistance lead to an increase in the risk of myocardial infarction (MI), stroke, heart failure (HF) as well as chronic kidney disease (CKD). Among the commercially available anti-hyperglycemic agents, incretin-based medications appear to be safe and effective in the treatment of type 2 diabetes mellitus (T2DM) and associated ca...
Source: Current Diabetes Reviews - August 10, 2023 Category: Endocrinology Authors: Sanket Seksaria Bhaskar Jyoti Dutta Mandeep Kaur Ghanshyam Das Gupta Surendra H Bodakhe Amrita Singh Source Type: research

Real ‐world risk of cardiovascular diseases in patients with type 2 diabetes associated with sodium–glucose cotransporter 2 inhibitors in comparison with metformin: A propensity score‐matched model analysis in Japan
Risk of CVD using SGLT2Is compared with metformin. AbstractWe aimed to compare the effects of cardiovascular disease risk in Japanese patients with type  2 diabetes on sodium–glucose cotransporter 2 inhibitors (SGLT2Is) or metformin. This retrospective, real-world cohort study was carried out using a claims database and propensity score matching; 58,402 eligible patients (29,201 per group) were included. The outcomes included nonfatal myocardi al infarction, angina pectoris, nonfatal stroke, hospitalization for heart failure and composite end-points. The hazard ratio (HR) for the composite end-point was 0.79, which w...
Source: Journal of Diabetes Investigation - July 31, 2023 Category: Endocrinology Authors: Takeshi Horii, Yoichi Oikawa, Akira Shimada, Kiyoshi Mihara Tags: SHORT REPORT Source Type: research

Differential Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiovascular and Renal Outcomes According to Renal Function: A Dose-Response Meta-Analysis Involving 10 Randomized Clinical Trials and 71,553 Individuals
CONCLUSION: The protective effects of SGLT2i for reducing most adverse cardiovascular and renal outcomes persisted in patients with variable degrees of renal impairment. The observed benefits such as preventing CV death, HF worsening, or stroke may be greater for patients with more severe CKD. Considering the cardiovascular and renal benefits associated with SGLT2i treatment, patients with CKD should be treated aggressively to improve outcomes.PROSPERO REGISTRATION NUMBER: CRD42021273500.PMID:37474112 | DOI:10.1093/ejendo/lvad078
Source: European Journal of Endocrinology - July 20, 2023 Category: Endocrinology Authors: Donna Shu-Han Lin An-Li Yu Hao-Yun Lo Cheng-Wei Lien Jen-Kuang Lee Fu-Tien Chiang Yu-Kang Tu Source Type: research

Women with PCOS have an increased risk for cardiovascular disease regardless of diagnostic criteria - a prospective population-based cohort study
CONCLUSIONS: PCOS should be considered a significant risk factor for CVD. Future follow-up will show how the risk of CVD events develops after menopausal age.PMID:37436934 | DOI:10.1093/ejendo/lvad077
Source: European Journal of Endocrinology - July 12, 2023 Category: Endocrinology Authors: M M Ollila R K Arffman E Korhonen L Morin-Papunen S Franks J Junttila T T Piltonen Source Type: research

External Validation of the BRAVO Diabetes Model Using the EXSCEL Clinical Trial Data
ConclusionsThis study demonstrates the feasibility of using the BRAVO model in settings where only fully de-identified patient-level data are available.
Source: Diabetes Therapy - July 11, 2023 Category: Endocrinology Source Type: research

Glucagon-like peptide-1 receptor agonists across the spectrum of heart failure
J Clin Endocrinol Metab. 2023 Jul 6:dgad398. doi: 10.1210/clinem/dgad398. Online ahead of print.ABSTRACTGlucagon-like peptide-1 receptor agonists (GLP-1 RA) have been used to reduce body weight in overweight or people with obesity and to improve glycemic control and cardiovascular outcomes among people with type 2 diabetes (T2D) and a high cardiovascular risk. However, the effects of GLP-1 RA may be modified by the presence of heart failure (HF). In this review, we summarize the evidence for the use of GLP-1 RA across patient's risk with a particular focus in HF. After a careful review of the literature, we challenge the c...
Source: The Journal of Clinical Endocrinology and Metabolism - July 6, 2023 Category: Endocrinology Authors: Jo ão Pedro Ferreira Abhinav Sharma Javed Butler Milton Packer Faiez Zannad Francisco Vasques-N óvoa Adelino Leite-Moreira Jo ão Sérgio Neves Source Type: research